{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T01:58:24Z","timestamp":1788141504430,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.diabres.2022.110210","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:10:21Z","timestamp":1670584221000},"page":"110210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"195","author":[{"given":"Qi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingnan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengbi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2022.110210_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2022.110210_b0010","doi-asserted-by":"crossref","unstructured":"Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42(2): 152-61.","DOI":"10.1093\/eurheartj\/ehaa736"},{"key":"10.1016\/j.diabres.2022.110210_b0015","doi-asserted-by":"crossref","unstructured":"Ito S, Kashihara N, Shikata K, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrology : CJASN 2020; 15(12): 1715-27.","DOI":"10.2215\/CJN.06870520"},{"issue":"23","key":"10.1016\/j.diabres.2022.110210_b0020","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.diabres.2022.110210_b0025","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2022.110210_b0030","doi-asserted-by":"crossref","unstructured":"Adamson C, Jhund PS. Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. Eur Heart J 2021; 43(6): 485-7.","DOI":"10.1093\/eurheartj\/ehab827"},{"key":"10.1016\/j.diabres.2022.110210_b0035","doi-asserted-by":"crossref","unstructured":"Xie Y, Bowe B, Mokdad AH, et al. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 2018; 94(3): 567-81.","DOI":"10.1016\/j.kint.2018.04.011"},{"issue":"3","key":"10.1016\/j.diabres.2022.110210_b0040","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.kint.2018.05.009","article-title":"Getting to know the enemy better\u2014the global burden of chronic kidney disease","volume":"94","author":"Jha","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.diabres.2022.110210_b0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.diabres.2022.110210_b0050","article-title":"Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabres.2022.110210_b0055","article-title":"Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.diabres.2022.110210_b0060","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliative Med"},{"key":"10.1016\/j.diabres.2022.110210_b0065","doi-asserted-by":"crossref","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43(6): 474-84.","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"10.1016\/j.diabres.2022.110210_b0070","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. Jama 2015; 314(9): 884-94.","DOI":"10.1001\/jama.2015.10081"},{"issue":"27","key":"10.1016\/j.diabres.2022.110210_b0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.diabres.2022.110210_b0080","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2022.110210_b0085","doi-asserted-by":"crossref","unstructured":"Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013; 34(31): 2453-63.","DOI":"10.1093\/eurheartj\/eht187"},{"key":"10.1016\/j.diabres.2022.110210_b0090","doi-asserted-by":"crossref","unstructured":"Sato N, Ajioka M, Yamada T, et al. A randomized controlled study of finerenone vs. eplerenone in japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease. Circulation J: Official J Japanese Circulation Soc 2016; 80(5): 1113-22.","DOI":"10.1253\/circj.CJ-16-0122"},{"key":"10.1016\/j.diabres.2022.110210_b0095","doi-asserted-by":"crossref","unstructured":"Wada T, Inagaki M, Yoshinari T, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrology 2021; 25(2): 120-30.","DOI":"10.1007\/s10157-020-01963-z"},{"key":"10.1016\/j.diabres.2022.110210_b0100","doi-asserted-by":"crossref","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension (Dallas, Tex : 1979) 2020; 75(1): 51-8.","DOI":"10.1161\/HYPERTENSIONAHA.119.13569"},{"issue":"1","key":"10.1016\/j.diabres.2022.110210_b0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.diabres.2022.110210_b0110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.diabres.2022.110210_b0115","doi-asserted-by":"crossref","first-page":"107701","DOI":"10.1016\/j.pharmthera.2020.107701","article-title":"Mineralocorticoid receptor antagonists in patients with chronic kidney disease","volume":"219","author":"Cosimato","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.diabres.2022.110210_b0120","doi-asserted-by":"crossref","unstructured":"Chung EY, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Systematic Rev 2020; 10(10): Cd007004.","DOI":"10.1002\/14651858.CD007004.pub4"},{"key":"10.1016\/j.diabres.2022.110210_b0125","doi-asserted-by":"crossref","unstructured":"Bonsu KO, Arunmanakul P, Chaiyakunapruk N. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic review and indirect comparison. Heart Failure Rev 2018; 23(2): 147-56.","DOI":"10.1007\/s10741-018-9679-y"},{"key":"10.1016\/j.diabres.2022.110210_b0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.diabres.2022.110210_b0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diabres.2022.110210_b0140","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/13543784.2021.2002844","article-title":"Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics","volume":"30","author":"Barrera-Chimal","year":"2021","journal-title":"Expert Opin Invest Drugs"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722010245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:24:35Z","timestamp":1759173875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722010245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"alternative-id":["S0168822722010245"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110210","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110210"}}